...
首页> 外文期刊>Respiratory Research >The differences of clinical characteristics and outcomes between imported and local patients of COVID-19 in Hunan: a two-center retrospective study
【24h】

The differences of clinical characteristics and outcomes between imported and local patients of COVID-19 in Hunan: a two-center retrospective study

机译:湖南进口和局部患者临床特征及成果的差异:双中心回顾性研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Abstract Background The clinical characteristics and outcomes of the 2019 novel coronavirus (COVID-19) pneumonia are different in Hubei compared to other regions in China. But there are few comparative studies on the differences between imported and local patients which may provide information of the different courses of the virus after transmission. Methods We investigated 169 cases of COVID-19 pneumonia in two centers in Hunan Province, and divided them into two groups according to epidemiological history, "imported patients" refers to patient with a clear history of travel in Wuhan within 14?days before onset, and " local patients” refers to local resident without a recent history of travel in Wuhan, aiming to analyze the difference in clinical characteristics and outcomes between the two groups. All the epidemiological, clinical, imaging, and laboratory data were analyzed and contrasted. Results The incidence of fever on admission in imported patients was significantly higher than local patients. There was a significantly higher proportion of abnormal pulmonary signs, hypokalemia, hyponatremia, prolonged PT, elevated D-dimer and elevated blood glucose in imported patients. Compared with local patients, the proportion using antibiotics, glucocorticoids and gamma globulin were significantly higher in imported patients. The moderate type was more common in local patients, and the severe type were more frequent in imported patients. In addition, the median duration of viral clearance was longer in imported patients. Conclusions In summary, we found that imported cases were more likely to develop into severe cases, compared with local patients and required more powerful treatments. Trial registration Registered 21st March 2020, and this study has been approved by the Medical Ethics Committee (Approved Number. 2020017).
机译:摘要背景,2019年新型冠状病毒(Covid-19)肺炎的临床特征和结果与中国其他地区相比湖北不同。但是对进口和本地患者之间的差异很少有可能提供传播后病毒不同课程信息的差异。方法研究湖南省两个中心的Covid-19肺炎患者169例,并根据流行病学历史分为两组,“进口患者”是指患者在武汉出现前14日在武汉旅行清晰历史,和“本地患者”是指在武汉最近旅行历史的地方居民,旨在分析两组临床特征和结果的差异。所有流行病学,临床,影像和实验室数据都被分析并形成对比。结果进口患者入院的发烧发病率明显高于局部患者。进口患者中肺症状,低钾血症,低钠血症,延长的PT,升高的D-二聚体和升高的血糖比例显着更高。与当地患者相比,进口患者中使用抗生素,糖皮质激素和γ球蛋白的比例显着高得多。莫德拉在局部患者中,TE型更常见,在进口患者中严重频繁频繁。此外,进口患者的病毒间隙中位数持续时间较长。总之,我们发现,与本地患者相比,进口病例更有可能发展成严重案件,并要求更强大的治疗。试用登记于2020年3月21日注册,本研究已被医疗伦理委员会批准(批准的号码。2020017)。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号